Table 5.
AMP derivation based on pre and/or in-hospital medication use: “all patients, by index event final diagnosis”
| STEMI (n=514) | UA/NSTEMI (n=520) | ||
|---|---|---|---|
| Antiplatelets, n (%) | |||
| None | 0 (0.0) | 0 (0.0) | |
| ASA only | 7 (1.4) | 48 (9.2) | |
| Clopidogrel only | 0 (0.0) | 4 (0.8) | |
| ASA + Clopidogrel | 404 (78.6) | 436 (83.8) | |
| ASA + GP IIb/IIIa | 2 (0.4) | 1 (0.2) | |
| Clopidogrel + GP IIb/IIIa | 1 (0.2) | 0 (0.0) | |
| ASA + Clopidogrel + GP IIb/IIIa | 100 (19.5) | 31 (6.0) | |
| By thrombolytic therapy | |||
| YES | 68 (13.2) | 0 (0.0) | |
| None† | 0 (0.0) | 0 (0.0) | |
| ASA + Clopidogrel | 67 (98.5) | 0 (0.0) | |
| ASA + GP IIb/IIIa | 0 (0.0) | 0 (0.0) | |
| Clopidogrel + GP IIb/IIIa | 0 (0.0) | 0 (0.0) | |
| ASA + Clopidogrel + GP IIb/IIIa | 1 (1.5) | 0 (0.0) | |
| NO | 446 (86.8) | 520 (100.0) | |
| None† | 0 (0.0) | 0 (0.0) | |
| ASA only | 7 (1.6) | 48 (9.2) | |
| Clopidogrel only | 0 (0.0) | 4 (0.8) | |
| ASA + Clopidogrel | 337 (75.6) | 436 (83.8) | |
| ASA + GP IIb/IIIa | 2 (0.4) | 1 (0.2) | |
| Clopidogrel + GP IIb/IIIa | 1 (0.2) | 0 (0.0) | |
| ASA + Clopidogrel + GP IIb/IIIa | 99 (22.2) | 31 (6.0) | |
| By anticoagulant therapy | |||
| YES | 482 (93.8) | 422 (81.2) | |
| None† | 0 (0.0) | 0 (0.0) | |
| ASA only | 6 (1.2) | 24 (5.7) | |
| Clopidogrel only | 0 (0.0) | 3 (0.7) | |
| GP IIb/IIIa only | 0 (0.0) | 0 (0.0) | |
| ASA + Clopidogrel | 373 (77.4) | 366 (86.7) | |
| ASA + GP IIb/IIIa | 2 (0.4) | 1 (0.2) | |
| Clopidogrel + GP IIb/IIIa | 1 (0.2) | 0 (0.0) | |
| ASA + Clopidogrel + GP IIb/IIIa | 100 (20.7) | 28 (6.6) | |
| NO | 32 (6.2) | 98 (18.8) | |
| None† | 0 (0.0) | 0 (0.0) | |
| ASA only | 1 (3.1) | 24 (24.5) | |
| Clopidogrel only | 0 (0.0) | 1 (1.0) | |
| ASA + Clopidogrel | 31 (96.9) | 70 (71.4) | |
| ASA + Clopidogrel + GP IIb/IIIa | 0 (0.0) | 3 (3.1) | |
| Number of antiplatelet medications | |||
| Total | 0 | 0 (0.0) | 0 (0.0) |
| 1 | 7 (1.4) | 52 (10.0) | |
| 2 | 402 (78.2) | 437 (84.0) | |
| 3 | 105 (20.4) | 31 (6.0) | |
| 4 | 0 (0.0) | 0 (0.0) | |
| By anticoagulant use | |||
| Unfractioned heparin | YES | 270 (52.5) | 193 (37.1) |
| 0 | 0 (0.0) | 0 (0.0) | |
| 1 | 3 (1.1) | 8 (4.1) | |
| 2 | 195 (72.2) | 171 (88.6) | |
| 3 | 72 (26.7) | 14 (7.3) | |
| 4 | 0 (0.0) | 0 (0.0) | |
| Low molecular weight heparinx | YES | 318 (61.9) | 284 (54.6) |
| 0 | 0 (0.0) | 0 (0.0) | |
| 1 | 4 (1.3) | 20 (7.0) | |
| 2 | 249 (78.3) | 242 (85.2) | |
| 3 | 65 (20.4) | 22 (7.7) | |
ASA - acetylsalicylic acid; GP IIb/IIIa - Glycoprotein IIb/IIIa inhibitors; NSTEMI - non- ST-segment elevation myocardial infarction; STEMI - ST-segment elevation myocardial infarction; UA-unstable angina. Table presents use of any loading or maintenance dose of listed medications pre- or in-hospital
did not take ASA, clopidogrel or a GP IIb/IIIa Inhibitor; may have received prasugrel or ticlopidine; *Time to treatment calculated as; #hours from symptom onset to first in-hospital administration of any of the associated medications, where data available missing dates/times of pre-and in-hospital medications replaced with the imputed date/time of hospital admission. Note-for patients with no in-hospital antiplatelet use recorded, any discharge antiplatelet is assumed to have also been used in-hospital